XISTA Life Sciences Advisory Board: Adding Scientific Depth to Investment Decisions

Strong life sciences investments require more than capital — they depend on deep scientific and industry expertise across multiple domains.

1 Min.

With the launch of its Life Sciences Advisory Board, XISTA brings together internationally recognized leaders: Werngard Czechtizky, Dirk Trauner, Michael Böhler, Tom Miller, and Holger Ottleben. Their backgrounds span medicinal chemistry, chemical biology, clinical development, biotech strategy, and pharmaceutical R&D, covering the full pathway from early discovery to commercialization.

The board is designed to play an active role in XISTA’s investment approach. It contributes to identifying emerging scientific opportunities at an early stage, strengthens decision-making through expert perspective, and supports founders as they translate complex research into real-world applications.

Rather than functioning as a symbolic addition, the advisory board reflects a structural commitment: integrating scientific depth directly into how investment decisions are made and how companies are built.

the members of the board sitting around a table with food